Table 1. Summary of data for each biomarker-drug combination.
| Biomarker – Drug combination | # of studies screened (# of studies curated) | Most common cancer studied (# of studies) | Other cancers studied (# of studies, if ≥ 2) | Overall Evidence |
|---|---|---|---|---|
| ERCC1 – Platinum agents | 266 (85) | Non-small cell lung cancer (43) | Ovarian cancer (10), Esophageal cancer (5), Small-cell lung cancer (4), Squamous cell head and neck cancers (HNSCC) (3), Colorectal cancer (3), Pancreatic cancer (2), Bladder cancer (2) | Consistent evidence from levels I-IV retrospective studies |
| MGMT – Temozolomide | 366 (55) | Gliomas (25) | Pituitary tumors (9), Melanoma (6), Neuroendocrine tumors (2) | Modest evidence from levels III-IV studies |
| RRM1 – Gemcitabine | 131 (55) | Non-small cell lung cancer (33) | Pancreatic cancer (7), Breast cancer (2) | Consistent evidence from levels I-IV retrospective studies |
| TS – 5-fluorouracil (5-FU), Capecitabine | 617 (55) | Colorectal cancer (27) | Gastric cancer (13), esophageal cancer (5), Hepatocellular cancer (2), Pancreatic cancer (2) | Modest evidence from levels III-IV studies |
| TUBB3 – Taxanes | 61 (40) | Non-small cell lung cancer (14) | Breast cancer (9), Gastric cancer (7), Ovarian cancer (3) Melanoma (2) | Modest evidence from levels III-IV studies |
| TOPO1 – Irinotecan, Topotecan | 50 (11) | Colorectal cancer (5) | Weak evidence from few level III and IV studies | |
| TOP2A – Anthracyclines | 62 (17) | Breast cancer (13) | Hepatocellular carcinoma (2) | Weak evidence from few level III and IV studies |
Total number of studies screened and curated based on our inclusion criteria; the most commonly represented cancers for each biomarker-drug combination and the overall evidence supporting the predictive effect of each biomarker.